Biologic modulators in allergic and autoinflammatory diseasesBroderick, Lori; Tourangeau, Louanne M.; Kavanaugh, Arthur; Wasserman, Stephen I.Current Opinion in Allergy and Clinical Immunology: August 2011 - Volume 11 - Issue 4 - p 355–360 doi: 10.1097/ACI.0b013e328348a882 Pharmacotherapy and evidence based medicine: Edited by David A. Khan and Enrico Compalati Abstract Author Information Purpose of review The advent of molecular techniques has resulted in the ability to tailor medications to specific protein targets. This review will emphasize several biological therapies, specifically directed toward cytokine receptors and inhibitors, and their role in the treatment of atopic and autoinflammatory diseases. Recent findings Translational research and the identification of the molecular pathophysiology of diseases have led to more targeted treatment approaches. The biologic modulators encompassing monoclonal antibodies as cytokine inhibitors, receptor blocking antibodies, and new fusion receptors are now being applied to diseases beyond their original application. Summary The expanded use of biological therapies has experienced success in the treatment of numerous disorders, especially in subsets of patients with disease that has been refractory to conventional therapies. aDivision of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, San Diego, California, USA Correspondence to Lori Broderick, MD, PhD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0635, La Jolla, CA 92093, USA Tel: +1 619 543 6428; e-mail: firstname.lastname@example.org Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.